Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
DRUG: Anlotinib|DRUG: Penpulimab
Progression-free survival (PFS), Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions., up to 24 months
Objective Response Rate (ORR), Objective response rate is defined as the percentage of subjects whose best response was complete response (CR) or partial response (PR) according to the RECIST v1.1, up to 24 months|Disease Control Rate (DCR), Disease control rate is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the RECIST v1.1., up to 24 months|Duration of Response (DOR), Duration of Response is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the RECIST v1.1 or death due to any cause, whichever occurs first., up to 24 months|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0)., Until 30 day safety follow-up visit|Overall Survival (OS), Overall Survival (OS) (median) is determined using the number of months measured from the initial date of treatment to the recorded date of death of participants., Up to 24 months
Number of TB cells count and interleukin-6/8/10, Objectives to analyse the subsets of TB cells and interleukin-6/8/10 associated treatment., through study completion, an average of 2 year
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)